{"entity":{"id":"nct03699475","kind":"trial","name":"Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS","aka":[],"tldr":"A phase 2/3 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, terminated.","summary":"Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS is a phase 2/3 interventional study registered as NCT03699475 by Bellicum Pharmaceuticals, with 1 participants enrolled, started 2018-12-27. Conditions recorded: Acute Myeloid Leukemia and Myelodysplastic Syndromes. Interventions recorded: rivogenlecleucel, rimiducid, Cyclophosphamide and haplo-HSCT.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03699475","url":"https://clinicaltrials.gov/study/NCT03699475"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds"],"sections":[],"technologies":[],"targets":[],"drugs":["rivogenlecleucel"],"companies":["bellicum"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03699475","phase":"2/3","setting":"A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS","sponsor":"Bellicum Pharmaceuticals","enrolled":1,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03699475/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"drug":[{"id":"rivogenlecleucel","kind":"drug","name":"Rivogenlecleucel","route":"/drugs/rivogenlecleucel/"}],"company":[{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/"}]}}